McKesson recalls Xanax blister packs with blank labels


McKesson Packaging Services is recalling blister packs of Xanax and a stomach drug because of labeling problems.

According to the most recent FDA Enforcement Report, McKesson is recalling 34,920 blister cards because the primary packaging label contains no product information--no product name, strength info, lot number or expiration date. The product was manufactured by Sandoz but packaged by McKesson’s North Carolina-based packaging operation and distributed in Colorado, Illinois, Louisiana and Ohio.

Additionally, the company is recalling 1,810 blister packs of the proton pump inhibitor Lansoprazole manufactured by Dr. Reddy’s Laboratories ($RDY) that were shipped nationwide. In that case, the blister packs' outer secondary packaging was mislabeled as 30-mg tablets instead of 40-mg tablets. The inner packaging is properly labeled, the report says.

Both voluntary recalls were issued this month.

The San Francisco-based drug wholesaling giant has been dealing with a variety of issues this year. In January it acknowledged it had eliminated 1,600 jobs, about 4% of its workforce. That announcement came after the company reduced its forecast for the fiscal year as generic pricing pressure and industry consolidation took a toll.

More recently, McKesson’s German distributor was raided by Germany’s Cartel Office a couple of weeks ago. Gehe was one of a number of wholesalers from which authorities reportedly seized documents as part of a probe into possible price collusion.  

- access the recall here

Related Articles:
Drug distributor McKesson laying off 1,600 
McKesson's German unit raided in price collusion probe


Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.